MINUTES

CPIC CONFERENCE CALL

DATE: March 1, 2012

PRESENT: Adriana Malheiro, Andrea Gaedigk, Caroline Thorn, Deanna Kroetz, Issam Zineh, Kristine Crews, Mary Relling, Michelle Carrillo, Nita Limdi, Min Song, Russell Wilke, Stuart Scott, Teri Klein, Todd Skaar, James Hoffman, Daniel Mueller.

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| GTR | Dr. Malheiro demonstrated the GTR site. No PGEN tests are live yet, but GTR has sought and received feedback from CPIC members on warfarin and clopidogrel guidelines. Strong support for prominent links to CPIC guidelines on left nav bar as true currently; suggestion to list PharmGKB as one of the “Clinical Resources” on home pages. Reiterated that PharmGKB will link to GTR for list of sites performing testing.  | Adriana will continue to seek CPIC input on pharmacogenetic tests. |
| CBZ and HLA guideline issues | Discussed proSusan led a discussion of the problem that most data linking \*1502 allele with TEN/SJS has been generated in Asians, due to small numbers of Europeans with 1502 allele. Consensus is that if a patient is known to be HLA-B\*1502 positive, then regardless of ethnicity, they should not be given CBZ. Also agreed that other HLA alleles associated with CBZ TEN/SJS should be discussed in this guideline, and that other related drugs that are also likely to have higher TEN/SJS in those with \*1502 should be discussed in this guideline. | Susan will make changes and circulate revised draft. |
| Submission to guidelines.gov | Marc Williams discussed depositing CPIC guidelines to guidelines.gov. He is working with Rochelle to re-format a guideline and assess what is needed for deposits.  | Marc and Mary will work with Rochelle Long to prioritize a guideline for deposit and report back to CPIC on plans.. |
| 2D6 phenotype assignments and scores | Andrea led the group through a discussion of how to assign activity scores to phenotypes, and whether all 2D6 alleles receive activity score values that accurately reflect their activity. Group agreed that (a) evidence must be reviewed on a drug-specific basis to be sure activity scores/phenotype assignments are reflected in summaries and (b) each CPIC guideline including CYP2D6 must define how alleles are defined scores, scores are assigned to phenotypes, and drug dosing is related to clear delineation of either scores, phenotypes, or both that is referenced and explained in each guideline.  | Andrea will work with TCA group and with SSRI group (with help from Kevin and Jesse) to define  |